


PHARMACEUTICAL 2017

KERYX BIOPHARMACEUTICALS INC Rank 238 of 313





PHARMACEUTICAL 2017

KERYX BIOPHARMACEUTICALS INC Rank 238 of 313

The relative strengths and weaknesses of KERYX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KERYX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 124% points. The greatest weakness of KERYX BIOPHARMACEUTICALS INC is the variable Net Income, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is -456%, being 39% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	132,897
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	21,551
Liabilities, Non-Current	1,040
Other Assets	1,111
Other Compr. Net Income	0
Other Expenses	40,789
Other Liabilities	127,132
Other Net Income	-38,252
Property and Equipment	4,211
Research and Development	29,504
Revenues	31,983
Selling, General and Administrative Expense	84,553

Output Variable	Value in 1000 USD
Assets	141,427
Liabilities	149,723
Expenses	154,846
Stockholders Equity	-8,296
Net Income	-161,115
Comprehensive Net Income	-161,115
Economic Capital Ratio	-456%